Eye Movement and Cognitive Dysfunction (EMCD)

January 18, 2020 updated by: Haotian Lin, Sun Yat-sen University

The Development of an Artificial Intelligence Platform for Screening and Referral of Cognitive Dysfunction

There is association between eye movement disorder and cognitive dysfunction. Therefore, utilizing eye movement and screening for cognitive dysfunction is feasible. In the present study, we will develop an artificial intelligence platform to screening for cognitive dysfunction by inspecting the function of eye movement. Futher more, based on the screening results, the platform will offer referral suggestions.

Study Overview

Status

Unknown

Conditions

Study Type

Observational

Enrollment (Anticipated)

700

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects who are over 45 years old with or without cognitive dysfunction.

Description

Inclusion Criteria:

  • ①Subjects who are diagnosed as mild cognitive decline, Alzheimer's disease, Vascular dementia, Lewy body dementia, Frontotemporal dementia, other dementia and normal by neurologist.
  • ②Subjects who can cooperate with the inspection.
  • ③Subjects who agree to participate in the study and sign the consent form

Exclusion Criteria:

  • ①Subjects who cannot do the inspection.
  • ②Subjects who suffer from diseases that compromise the inspection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Normal
Subjects over 45 years old without cognitive dysfunction
Mild cognitive decline
Subjects who are diagnosed as mild cognitive decline(MCI) according to neurologists.
Alzheimer's disease
Subjects who are diagnosed as Alzheimer's disease(AD) according to neurologists.
Vascular dementia
Subjects who are diagnosed as vascular dementia(VD) according to neurologists.
Lewy body dementia
Subjects who are diagnosed as Lewy body demenita (DLB) according to neurologists.
Frontotemporal dementia
Subjects who are diagnosed as Frontotemporal demenita (FD) according to neurologists.
Other dementia
Subjects who are diagnosed as dementia but are not as AD, VD, DLB OR FD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area under the curve
Time Frame: up to 1 month
AUC values for predicting whether subject has cognitive impairment or not
up to 1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy, true positive rate, and true negetive rate
Time Frame: up to 1 month
The performance of this artificial platform
up to 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sun Yat-sen University

Investigators

  • Study Chair: Haotian Lin, M.D.,Ph.D, Zhongshan Ophthalmic Center, Sun Yat-sen University
  • Study Director: Xun Wang, M.D.,Ph.D, Zhongshan Ophthalmic Center, Sun Yat-sen University
  • Principal Investigator: Shuyi Zhang, M.D., Zhongshan Ophthalmic Center, Sun Yat-sen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

February 1, 2020

Primary Completion (ANTICIPATED)

August 1, 2020

Study Completion (ANTICIPATED)

December 1, 2020

Study Registration Dates

First Submitted

January 18, 2020

First Submitted That Met QC Criteria

January 18, 2020

First Posted (ACTUAL)

January 22, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 22, 2020

Last Update Submitted That Met QC Criteria

January 18, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Eye movement-cognitive decline

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Dysfunction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe